183 related articles for article (PubMed ID: 12952287)
1. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.
Witham TF; Villa L; Yang T; Pollack IF; Okada H; Robbins PD; Chambers WH
J Neurooncol; 2003; 64(1-2):63-9. PubMed ID: 12952287
[TBL] [Abstract][Full Text] [Related]
2. NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function.
Chambers WH; Bozik ME; Brissette-Storkus SC; Basse P; Redgate E; Watkins S; Boggs SS
Cancer Res; 1996 Aug; 56(15):3516-25. PubMed ID: 8758920
[TBL] [Abstract][Full Text] [Related]
3. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
4. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
Fakhrai H; Dorigo O; Shawler DL; Lin H; Mercola D; Black KL; Royston I; Sobol RE
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2909-14. PubMed ID: 8610141
[TBL] [Abstract][Full Text] [Related]
5. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
[TBL] [Abstract][Full Text] [Related]
6. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
7. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors.
Manome Y; Wen PY; Hershowitz A; Tanaka T; Rollins BJ; Kufe DW; Fine HA
Cancer Immunol Immunother; 1995 Oct; 41(4):227-35. PubMed ID: 7489565
[TBL] [Abstract][Full Text] [Related]
8. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1.
Roth P; Mittelbronn M; Wick W; Meyermann R; Tatagiba M; Weller M
Cancer Res; 2007 Apr; 67(8):3540-4. PubMed ID: 17440061
[TBL] [Abstract][Full Text] [Related]
9. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas.
Yang T; Witham TF; Villa L; Erff M; Attanucci J; Watkins S; Kondziolka D; Okada H; Pollack IF; Chambers WH
Cancer Res; 2002 May; 62(9):2583-91. PubMed ID: 11980653
[TBL] [Abstract][Full Text] [Related]
10. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats.
DiMeco F; Rhines LD; Hanes J; Tyler BM; Brat D; Torchiana E; Guarnieri M; Colombo MP; Pardoll DM; Finocchiaro G; Brem H; Olivi A
J Neurosurg; 2000 Mar; 92(3):419-27. PubMed ID: 10701528
[TBL] [Abstract][Full Text] [Related]
11. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells.
Kulprathipanja NV; Kruse CA
J Neuroimmunol; 2004 Aug; 153(1-2):76-82. PubMed ID: 15265665
[TBL] [Abstract][Full Text] [Related]
12. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.
Laterra J; Nam M; Rosen E; Rao JS; Lamszus K; Goldberg ID; Johnston P
Lab Invest; 1997 Apr; 76(4):565-77. PubMed ID: 9111517
[TBL] [Abstract][Full Text] [Related]
13. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
14. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
15. CD161B:ClrB interactions mediate activation of enhanced lysis of tumor target cells following NK cell:DC co-culture.
Yang T; Flint MS; Webb KM; Chambers WH
Immunol Res; 2006; 36(1-3):43-50. PubMed ID: 17337765
[TBL] [Abstract][Full Text] [Related]
16. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Saito R; Bringas J; Mirek H; Berger MS; Bankiewicz KS
J Neurosurg; 2004 Nov; 101(5):826-31. PubMed ID: 15540922
[TBL] [Abstract][Full Text] [Related]
17. Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen.
Ginzkey C; Eicker S; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn M; Steinmann J; Hamel W
Acta Neurochir (Wien); 2013 Jan; 155(1):51-8; discussion 59. PubMed ID: 23132370
[TBL] [Abstract][Full Text] [Related]
18. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
Schiltz PM; Gomez GG; Read SB; Kulprathipanja NV; Kruse CA
J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the 9L gliosarcoma implanted in the Fischer rat: an orthotopic model for a grade IV brain tumor.
Bouchet A; Bidart M; Miladi I; Le Clec'h C; Serduc R; Coutton C; Regnard P; Khalil E; Dufort S; Lemasson B; Laissue J; Pelletier L; Le Duc G
Tumour Biol; 2014 Jul; 35(7):6221-33. PubMed ID: 24633919
[TBL] [Abstract][Full Text] [Related]
20. The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting.
Hagenaars M; Ensink NG; Jonges LE; Chambers WH; Eggermont AM; van de Velde CJ; Fleuren GJ; Kuppen PJ
Immunobiology; 1999 Feb; 200(1):31-48. PubMed ID: 10084694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
